Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives Consensus Recommendation of “Buy” from Analysts

Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) have been given a consensus recommendation of “Buy” by the six research firms that are covering the firm, Marketbeat.com reports. Five research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $25.60.

A number of brokerages have commented on ATXS. HC Wainwright restated a “buy” rating and set a $16.00 price objective on shares of Astria Therapeutics in a research note on Monday, January 13th. Oppenheimer upped their price target on Astria Therapeutics from $26.00 to $28.00 and gave the stock an “outperform” rating in a report on Thursday, November 14th.

Institutional Investors Weigh In On Astria Therapeutics

Hedge funds have recently bought and sold shares of the business. FMR LLC boosted its stake in shares of Astria Therapeutics by 29.2% during the 3rd quarter. FMR LLC now owns 7,822,275 shares of the biotechnology company’s stock valued at $86,123,000 after buying an additional 1,767,714 shares during the last quarter. RA Capital Management L.P. boosted its stake in Astria Therapeutics by 1.2% during the 3rd quarter. RA Capital Management L.P. now owns 5,105,213 shares of the biotechnology company’s stock valued at $56,208,000 after acquiring an additional 61,457 shares during the last quarter. Vestal Point Capital LP grew its holdings in Astria Therapeutics by 23.1% during the 3rd quarter. Vestal Point Capital LP now owns 4,000,000 shares of the biotechnology company’s stock worth $44,040,000 after acquiring an additional 750,000 shares in the last quarter. Millennium Management LLC increased its position in shares of Astria Therapeutics by 13.5% in the 2nd quarter. Millennium Management LLC now owns 1,842,063 shares of the biotechnology company’s stock worth $16,763,000 after purchasing an additional 218,518 shares during the last quarter. Finally, Affinity Asset Advisors LLC raised its stake in shares of Astria Therapeutics by 15.4% in the 2nd quarter. Affinity Asset Advisors LLC now owns 975,606 shares of the biotechnology company’s stock valued at $8,878,000 after purchasing an additional 130,000 shares in the last quarter. Institutional investors and hedge funds own 98.98% of the company’s stock.

Astria Therapeutics Trading Down 3.2 %

Shares of ATXS stock opened at $7.50 on Monday. The company has a market cap of $423.23 million, a PE ratio of -3.59 and a beta of 0.70. The company’s fifty day simple moving average is $9.43 and its 200-day simple moving average is $10.64. Astria Therapeutics has a 52 week low of $6.95 and a 52 week high of $16.90.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.